AstraZeneca employees suspected of insurance fraud have made new progress.
In February 10th, the official account of WeChat medical insurance of Shenzhen Medical Insurance Bureau issued the briefing on the case of staff suspected of cheating the medical insurance fund by Shenzhen medical insurance company. In July 2021, according to the clues, the Shenzhen Medical Insurance Bureau found that employees of the company were suspected of fraud and fraud, and were instruct under the National Health Insurance Bureau. Cooperate with Shenzhen Public Security Bureau and other relevant units to carry out special investigation and handling. After careful work, the case was successfully solved, a fraud Gang suspected of tampering with the genetic test results of tumor patients to defraud the medical insurance fund was destroyed, 17 persons involved were arrested, and all criminal coercive measures were taken in accordance with the law.
In response to this matter, the reporter of Securities Daily contacted AstraZeneca for an interview. However, relevant people of the company told reporters that the company has no more information response at present.
In response, lawyer Yang Zhaoquan, director of Beijing Weinuo law firm, said in an interview with this newspaper that if you are not an employee in an important position, it should have little impact on the company.
the National Medical Insurance Bureau continued to increase the scale to deal with insurance fraud
On the eve of the Spring Festival in the year of the tiger, the National Medical Insurance Administration issued an article entitled “response to the staff of AstraZeneca Pharmaceutical Co., Ltd. suspected of defrauding medical insurance funds”, which caused a sensation in the industry.
According to the above documents, in view of the staff of AstraZeneca Pharmaceutical Co., Ltd. suspected of tampering with the genetic test results of tumor patients to defraud the medical insurance fund, the head of the fund supervision department of the national medical insurance administration said that in the early stage, according to the clues reported by the masses, the national medical insurance administration urged Shenzhen to establish a joint task force composed of medical insurance, public security, health and health, market supervision and other departments, The criminal suspect has been arrested for thorough investigation of the case.
Recently, the national medical insurance bureau and the Ministry of public security interviewed the relevant persons in charge of AstraZeneca China, informed the progress of the phased investigation of the case, and required AstraZeneca China to strictly abide by laws and regulations, fully cooperate with relevant departments in follow-up investigation, immediately carry out internal investigation and rectification, plug the loopholes in marketing supervision, strengthen the law-abiding education of employees and effectively enhance the awareness of integrity, Timely expose the interview and rectification. According to the interview requirements, AstraZeneca China timely connected with Shenzhen medical insurance bureau and Public Security Bureau to do a good job in the follow-up investigation of the case, urged employees who have similar behaviors to voluntarily surrender, and announced the case and self inspection and rectification on the enterprise’s official website.
Next, the National Medical Insurance Bureau will cooperate with the Ministry of public security and the National Health Commission to carry out special rectification on tampering with genetic test results to defraud medical insurance funds nationwide.
For the above suspected insurance fraud, AstraZeneca released more information on its official website on the same day.
According to AstraZeneca’s official website, in August 2021, AstraZeneca found in its internal compliance inspection that a small number of employees in Shenzhen tampered with or participated in tampering with patient test reports, suspected of defrauding medical insurance funds. The company attaches great importance to this, sincerely accepts the guidance and suggestions of the national medical insurance bureau and the public security department, and will fully implement the relevant requirements, further strengthen the management and supervision, continuously improve the employees’ awareness of laws and regulations, and ensure that the legal compliance is implemented in the daily work of each employee.
AstraZeneca said that the company will continue to carry out targeted internal self inspection and self correction actions to prevent any suspected insurance fraud and other violations of law and discipline. Meanwhile, AstraZeneca China will continue to strengthen the compliance culture, compliance training system and self inspection system, and strengthen the supervision of business activities to ensure the sustainable and healthy development of the company’s business under the premise of legal compliance.
China’s performance is expected to decline this year
According to AstraZeneca’s official website, the company has entered the Chinese market since 1993. China is one of AstraZeneca’s most important markets and the company’s growth engine. The company’s key treatment fields include respiratory, cardiovascular, metabolic, tumor, digestion, kidney and rare diseases, among which the tumor field includes oshitinib mesylate tablets, gefitinib tablets, duvalizumab injection and other products. At present, the total market value of AstraZeneca is about $181.6 billion.
On February 10, AstraZeneca announced its 2021 results. Throughout the year, the company achieved a revenue of US $37.417 billion, a year-on-year increase of 41%, and the net profit attributable to the common shareholders of the parent company was US $112 million, a year-on-year decrease of 96.5%; Among them, the fourth quarter increased by 62% to US $12.011 billion, and the net profit attributable to common shareholders of the parent company in the fourth fiscal quarter was US $347 million, a year-on-year decrease of 134.29%.
China is one of the important sources of AstraZeneca’s revenue. In 2021, the revenue reached US $6.011 billion, a year-on-year increase of 12%. However, the Chinese business decreased by 4% year-on-year for the first time in the fourth quarter, and the revenue decreased to $1.312 billion from $1.362 billion in the same period in fiscal 2020. In the financial guidance provided in 2022, AstraZeneca expects that the performance of China may decline in the median single digit ratio in 2022, mainly due to the continuous impact of centralized procurement and medical insurance.
It is worth mentioning that since last year, AstraZeneca’s business team has continued to adjust. Among them, on December 9, 2021, AstraZeneca announced that Yin min, general manager of its China Cancer division, would leave the company, and the last working day was December 31. On February 10, he Shuzhen, head of AstraZeneca and the county team, officially resigned and became one of the many executives who left AstraZeneca.
In addition, on the evening of January 4, 2022, the listed company Shanghai Junshi Biosciences Co.Ltd(688180) announced that on December 31, 2021, the company signed the termination agreement of exclusive promotion agreement with AstraZeneca pharmaceutical, and the company withdrew the promotion right of treprizumab injection agreed in the original agreement. It is understood that the cooperation between Shanghai Junshi Biosciences Co.Ltd(688180) and AstraZeneca was reached on February 28, 2021. The cooperation between the two sides lasted only 10 months. The cooperation ended in such a short time, which attracted market attention.
